HCPCS
J1568
1 unit = 500 mg
Phase 1
Identify what you're billing
The 500 mg unit basis is the #1 source of denials — nail it first.
The 500 mg unit basis — biller error trap CMS HCPCS verified May 2026
J1568 is one of a small group of J-codes that bill on a 500 mg unit basis instead of the usual 1 mg.
Most specialty drug J-codes use a 1 mg = 1 unit convention (Opdivo J9299, Rituxan J9312, Tecentriq J9022, Herceptin J9355, etc.). IVIG codes are the exception — J1568 (Octagam), J1569 (Gammagard Liquid), J1459 (Privigen), J1561 (Gamunex-C / Gammaked), J1572 (Flebogamma DIF), and J1599 (unspecified IVIG) all bill on a 500 mg unit basis.
If you bill grams as units, you will be off by 1,000×. A 30 g dermatomyositis
cycle is 60 units (30,000 mg ÷ 500), not 30,000 units. Auditors and claims systems may catch the error;
many do not. A single overbilled claim can trigger a payer takeback that exceeds the entire patient's benefit.
Conversion cheat sheet
| Dose (mg) | Dose (g) | J1568 units | Math |
|---|---|---|---|
| 5,000 mg | 5 g | 10 units | 5,000 ÷ 500 |
| 10,000 mg | 10 g | 20 units | 10,000 ÷ 500 |
| 20,000 mg | 20 g | 40 units | 20,000 ÷ 500 |
| 28,000 mg | 28 g | 56 units | 70 kg × 400 mg/kg PI dose |
| 35,000 mg | 35 g | 70 units | 70 kg × 500 mg/kg ITP-day |
| 70,000 mg | 70 g | 140 units | 70 kg × 1 g/kg ITP day |
| 140,000 mg | 140 g | 280 units | 70 kg × 2 g/kg DM cycle (split across 2–5 days) |
Octagam 5% vs Octagam 10% FDA label verified May 2026
Same J-code, different concentrations and different FDA-approved indications.
Octapharma markets two liquid IVIG concentrations under the Octagam brand. They share the J-code (J1568) but carry different FDA-approved indications and different bottle inventories. Pick the right concentration for the indication; document accordingly.
| Octagam 5% liquid | Octagam 10% liquid | |
|---|---|---|
| HCPCS | J1568 | J1568 |
| Concentration | 50 mg/mL | 100 mg/mL |
| Bottle sizes | 1 g/20 mL, 2.5 g/50 mL, 5 g/100 mL, 10 g/200 mL, 25 g/500 mL | 1 g/10 mL, 2 g/20 mL, 5 g/50 mL, 10 g/100 mL, 20 g/200 mL, 30 g/300 mL |
| FDA-approved PI | Yes | Yes |
| FDA-approved ITP | Yes (chronic ITP) | Per label |
| FDA-approved dermatomyositis | NO | YES — first IVIG with DM approval (Aug 2021) |
| Initial infusion rate | 0.01 mL/kg/min | 0.5 mg/kg/min |
| Maximum infusion rate | 0.04 mL/kg/min | 12 mg/kg/min |
| Volume for 2 g/kg in 70 kg pt | 2,800 mL | 1,400 mL (half the volume) |
| Original FDA approval | 2004 | 2014 (PI/ITP); 2021 added DM indication |
Why concentration matters operationally: The 10% formulation delivers the same gram dose in half
the volume. For a 2 g/kg dermatomyositis cycle in a 70 kg patient, that's 1,400 mL (10%) vs 2,800 mL (5%) per
cycle — meaningful for chair time, fluid management in patients with cardiac/renal limits, and
infusion-pump scheduling.
Concentration is NOT interchangeable for indication. Octagam 5% is not FDA-approved for DM.
If a payer audit finds a DM patient was infused with the 5% formulation, the claim is at risk
even though both products bill under J1568. Document the concentration in the medical record (lot number /
bottle size) and on the infusion log.
Indication-specific dosing & unit math FDA label May 2026
From the FDA prescribing information for Octagam 5% and Octagam 10% (Octapharma USA).
Primary humoral immunodeficiency (PI) — Octagam 5%
- 300–600 mg/kg IV every 3–4 weeks
- Adjust dose & interval to achieve target IgG trough 500–1000 mg/dL
- Typical: 12–17 doses/year
- Example: 70 kg patient at 400 mg/kg = 28 g per infusion = 56 units J1568
Chronic immune thrombocytopenic purpura (ITP) — Octagam 5%
- 1 g/kg/day × 1–2 consecutive days
- Repeat course as platelet response dictates
- Example: 70 kg patient at 1 g/kg = 70 g per day = 140 units J1568 per infusion day
Adult dermatomyositis (DM) — Octagam 10% only
- 2 g/kg per cycle, divided over 2–5 consecutive days, every 4 weeks
- Per-cycle total: 70 kg patient = 140 g = 280 units J1568 (across 2–5 days)
- Bill per infusion day with the units administered that day
Worked example — first cycle for a 70 kg DM patient on Octagam 10%
# Cycle: 2 g/kg = 140 g over 2-5 days, q4 weeks
Total cycle dose: 140 g = 140,000 mg
Total cycle units: 280 units (140,000 ÷ 500)
# Split over 5 days at 28 g/day:
Per-day dose: 28 g = 28,000 mg
Per-day units: 56 units J1568
Per-day vials: 1 × 30 g/300 mL bottle (waste applies if < 30 g infused)
OR: 2 × 20 g/200 mL bottles + adjust down
# Per-day claim:
J1568 (56 units) + JZ + 96365 (initial hour) + 96366 (each additional hour)
ICD-10: M33.10 or appropriate dermatomyositis code
# Per-cycle Medicare ASP+6% (Q2 2026):
280 units × $47.035 = ~$13,170 per cycle drug only
Total cycle dose: 140 g = 140,000 mg
Total cycle units: 280 units (140,000 ÷ 500)
# Split over 5 days at 28 g/day:
Per-day dose: 28 g = 28,000 mg
Per-day units: 56 units J1568
Per-day vials: 1 × 30 g/300 mL bottle (waste applies if < 30 g infused)
OR: 2 × 20 g/200 mL bottles + adjust down
# Per-day claim:
J1568 (56 units) + JZ + 96365 (initial hour) + 96366 (each additional hour)
ICD-10: M33.10 or appropriate dermatomyositis code
# Per-cycle Medicare ASP+6% (Q2 2026):
280 units × $47.035 = ~$13,170 per cycle drug only
Worked example — PI patient on Octagam 5%, monthly maintenance
# 70 kg patient, 400 mg/kg q4 weeks Octagam 5%
Per-infusion dose: 28 g = 28,000 mg = 56 units
Bottles: 2 × 10 g/200 mL + 1 × 5 g/100 mL + 1 × 2.5 g/50 mL + 1 × 1 g/20 mL (or vial mix to total 28 g)
Admin: 96365 + 96366 (typical 2–4 hour infusion)
# Annual (13 doses):
Total annual units: 728 units
Annual drug cost (Q2 2026 ASP+6%): ~$34,242 before sequestration
Per-infusion dose: 28 g = 28,000 mg = 56 units
Bottles: 2 × 10 g/200 mL + 1 × 5 g/100 mL + 1 × 2.5 g/50 mL + 1 × 1 g/20 mL (or vial mix to total 28 g)
Admin: 96365 + 96366 (typical 2–4 hour infusion)
# Annual (13 doses):
Total annual units: 728 units
Annual drug cost (Q2 2026 ASP+6%): ~$34,242 before sequestration
Dermatomyositis indication — Octagam 10% specifically FDA Aug 2021
First IVIG with an FDA-approved dermatomyositis indication. Approved August 2021 based on the ProDERM trial.
Before August 2021, IVIG was used off-label in dermatomyositis based on small trials, ACR consensus, and published case series. Octagam 10% changed that — the ProDERM trial (NEJM, 2022) was the pivotal Phase 3 placebo-controlled study showing superiority on the Total Improvement Score (TIS) at week 16. FDA approved the dermatomyositis indication for Octagam 10% in August 2021. As of Q2 2026, Privigen 10% has also obtained DM approval, but Octagam 10% retains first-mover positioning and a substantial body of payer-recognized DM evidence.
Why this matters for prior auth
- Many payers now require FDA-labeled IVIG product for DM (not just any IVIG); off-label brands may face higher PA bar
- Octagam 10% PA submissions for DM are typically straightforward when ICD-10 + diagnosis criteria are documented
- Payers may require failed first-line therapy (corticosteroids, methotrexate, azathioprine, or MMF) before IVIG approval
- Re-authorization typically requires functional improvement documentation (manual muscle testing, TIS components, or skin score)
Diagnosis support documentation
- Serology: anti-Mi-2, anti-TIF1γ, anti-NXP-2, anti-MDA5, or anti-Jo-1 (myositis-specific autoantibodies)
- Muscle biopsy or MRI when clinically indicated
- EMG findings consistent with myopathy
- Characteristic skin findings (Gottron's papules, heliotrope rash, V-sign, shawl sign)
- CK elevation (typical but not required — some MDA5+ patients have normal CK)
ICD-10 coding for DM (Octagam 10%):
M33.0x (juvenile dermatomyositis — note: Octagam 10% FDA approval is for adults),
M33.1x (other dermatomyositis — most adult DM),
M33.20–M33.29 (polymyositis with myopathy),
M33.9x (dermatopolymyositis, unspecified). Use 5th-character specificity where
documentation supports it.
Infusion rate titration FDA label May 2026
Different rates for 5% vs 10% — in different units (mL/kg/min vs mg/kg/min).
| Formulation | Initial rate | Increment | Maximum rate | Notes |
|---|---|---|---|---|
| Octagam 5% | 0.01 mL/kg/min (~30 mg/kg/hour) | Increase q15 min if tolerated | 0.04 mL/kg/min (~120 mg/kg/hour) | Patients at risk for renal/thrombotic complications: stay at lower end |
| Octagam 10% | 0.5 mg/kg/min (~30 mg/kg/hour) | Increase q15–30 min if tolerated | 12 mg/kg/min (~720 mg/kg/hour) | Slow rates required for elderly, renal impairment, or thrombotic risk |
Watch the units. Octagam 5% rate is in mL/kg/min; Octagam 10% rate is in mg/kg/min.
Pharmacy and infusion-suite policies should explicitly call out the formulation to avoid mix-ups.
Adverse infusion-rate-related reactions (headache, fever, chills, flushing) typically resolve by slowing the infusion.
Boxed warning — thrombosis, renal dysfunction, acute renal failure. Class warning
for all IVIG products. Hydrate adequately, slow infusion in at-risk patients, monitor renal function
baseline + during therapy, screen for thrombotic risk factors (advanced age, prolonged immobilization,
hyperviscosity, catheters, history of thrombosis).
Brand interchangeability — Octagam vs other major IVIG brands CMS Q2 2026
Octagam is currently the lowest-cost major IVIG on Medicare ASP+6%. Payer formulary decisions often override.
All major brand IVIG products meet FDA potency, purity, and safety standards. Clinically, brands differ in IgA content, sugar content, sodium, osmolarity, and pH — relevant for patients with prior IgA deficiency reactions, sodium-restricted diets, or osmotic-load concerns. For most patients, brand choice is driven by payer formulary, hospital contracting, and supply availability rather than clinical superiority.
Q2 2026 ASP+6% comparison — major brand IVIG products
| Brand | HCPCS | Manufacturer | ASP+6% / 500 mg unit | FDA DM indication? |
|---|---|---|---|---|
| Octagam (5% & 10%) | J1568 | Octapharma | $47.035 — lowest | Yes (10% only, Aug 2021 — first IVIG) |
| Privigen (10%) | J1459 | CSL Behring | ~$49.533 | Yes (added later) |
| Gammagard Liquid (10%) | J1569 | Takeda | ~$49.081 | No |
| Gamunex-C / Gammaked (10%) | J1561 | Grifols / Kedrion | ~$49.726 | No |
| Flebogamma DIF (5%, 10%) | J1572 | Grifols | ~$48.5 | No |
| Hizentra (SC IgG) → | J1559 | CSL Behring | SC formulation, separate code | No (SC IgG, different dosing paradigm) |
Lowest-cost positioning: Octagam J1568 carries the lowest Medicare ASP+6% of the
major brand IVIG products as of Q2 2026. For payers running cost-driven formulary or value-based
contracts, Octagam is often the preferred IVIG. For DM specifically, Octagam 10% combines lowest cost
with first-mover FDA approval — a strong combination.
Payer overrides are common. Many commercial payers and PBM-owned medical-benefit programs
have brand-specific contracts with Privigen, Gammagard Liquid, or Gamunex-C. Verify the specific payer's
IVIG preferred brand before infusing. Brand switching mid-therapy is generally avoided due to
differences in osmolarity, sodium, sugar, IgA — document clinical rationale if a switch is required.
Cross-reference: other major IVIG brand pages
- Privigen (J1459) — CSL Behring, 10% liquid, DM indication added
- Gammagard Liquid (J1569) — Takeda, 10% liquid
- Gamunex-C (J1561) — Grifols, 10% liquid
- Hizentra (J1559) — CSL Behring, SC IgG (different admin paradigm)
Phase 2
Code the claim
Non-chemo IV admin, JZ on every adult claim, indication-specific ICD-10.
Administration codes CPT verified May 2026
IVIG is therapeutic IV (non-chemo). Use 96365 for the initial hour, 96366 for each additional hour.
| Code | Description | When to use |
|---|---|---|
96365 |
IV infusion, for therapy/prophylaxis/diagnosis (specify substance/drug); initial, up to 1 hour | Primary code for Octagam. One unit per infusion day. |
96366 |
IV infusion; each additional hour (List separately in addition to primary) | Bill for each additional hour beyond the first. IVIG infusions typically run 2–6 hours. |
96367 |
IV infusion, additional sequential infusion of a new drug/substance, up to 1 hour | Pre-medications infused sequentially (e.g., methylprednisolone) when separately documented. |
96413 / 96415 |
Chemotherapy administration codes | NOT appropriate. Octagam is not chemotherapy. Use 96365/96366. |
Multi-day DM cycles: For a 2 g/kg dermatomyositis cycle split over 2–5 consecutive
days, bill 96365 + 96366 (and J1568) on each infusion day. Each day is a separate encounter. Do not
bundle multi-day cycles onto a single claim.
Modifiers CMS verified May 2026
JZ — required on virtually every adult claim
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Octagam bottles are single-dose containers. When an entire bottle (or combination of bottles totaling the prescribed dose) is administered with no waste, bill JZ.
JW — partial-bottle waste
IVIG dosing is weight-based, so partial-bottle waste is common. Example: a 70 kg patient on 400 mg/kg for PI = 28 g. Using a 30 g bottle leaves 2 g (4 units) of waste — bill JW with the wasted units on a separate claim line. Optimize bottle selection to minimize waste (combine 25 g + 2.5 g + 1 g instead of one 30 g) when payer policy allows. One of JZ or JW must be on every J1568 claim.
Waste discipline matters. Many practices over-bill JZ when they should bill JW for the
partial-bottle remainder. CMS audits will look at typical IVIG bottle inventory vs the dose billed.
Pick the bottle combination closest to the prescribed dose; document the discarded portion.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion. Routine pre-infusion clinical assessment is bundled.
340B modifiers (JG, TB)
For 340B-acquired Octagam, follow your MAC's current 340B modifier policy. Octapharma OneSource does not provide 340B-specific instructions.
ICD-10-CM by indication FY2026 verified May 2026
Use the most specific code supported by the encounter documentation. Indication-specific codes drive PA approval.
| Indication | Octagam formulation | ICD-10 family | Notes |
|---|---|---|---|
| Primary humoral immunodeficiency (CVID, X-linked agammaglobulinemia, IgG subclass deficiency, etc.) | 5% | D80.x, D81.x, D82.x | Most specific available; D80.0 (hereditary hypogammaglobulinemia), D80.1 (non-familial hypogammaglobulinemia), D83.x (CVID) |
| Chronic immune thrombocytopenic purpura (ITP) | 5% | D69.3 | Acute/chronic distinction in documentation; primary code D69.3 |
| Adult dermatomyositis (FDA-labeled, Aug 2021) | 10% only | M33.10–M33.19 | Other dermatomyositis (most adult DM); 4th/5th character specificity per documentation |
| Juvenile dermatomyositis | 10% (off-label adult-approval; pediatric use per clinical judgment) | M33.00–M33.09 | JDM — verify payer position; FDA indication is adult DM |
| Polymyositis with myopathy | 10% (per DM indication framework) | M33.20–M33.29 | Some payers extend DM coverage to PM; verify policy |
| Dermatopolymyositis, unspecified | 10% | M33.90–M33.99 | Use only when more specific code not supported |
Indication-specific PA criteria are the norm for IVIG. Most payers require ICD-10
code, prior therapy history, dose justification (mg/kg), and concentration/brand. The ICD-10 code alone
is not sufficient for approval. Off-label IVIG indications (Guillain-Barré, CIDP, MMN, MG, etc.)
may need different brand/code — verify before infusing.
Site of care & place of service Verified May 2026
IVIG is heavily site-of-care managed by all major commercial payers. UnitedHealthcare, Aetna, and Cigna actively steer IVIG away from hospital outpatient (HOPD) settings to home infusion or ambulatory infusion centers (AICs). Home infusion is increasingly preferred for stable PI maintenance patients; AIC for ITP and DM cycles where monitoring needs are higher.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Patient home (home infusion) | 12 | CMS-1500 / 837P (home infusion vendor) | Preferred for stable PI maintenance — UHC, Aetna, Cigna actively push here |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred for ITP, DM cycles, new starts, clinical instability |
| Physician office | 11 | CMS-1500 / 837P | Acceptable; common for sub-specialty practices (rheum, immuno) |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored; PA likely required after first 1–3 cycles |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored; PA likely required after first 1–3 cycles |
Home infusion is the dominant trend for PI maintenance. Stable PI patients on
Octagam 5% maintenance often transition to home infusion within 6–12 months. Dermatomyositis
cycles (2 g/kg over 2–5 days) are typically AIC-based given the volume, multi-day schedule, and
monitoring requirements. UHC site-of-care steering programs (Optum) and Aetna site-of-care policy actively
push HOPD-to-AIC/home transitions.
Hospital outpatient claims after the first cycle are at risk. Payers will frequently
deny continued HOPD admin without medical-necessity documentation (cardiac/renal monitoring needs, prior
severe reactions, lack of stable IV access at home). Plan the transition to AIC or home before the
first cycle ends.
Claim form field mapping Octapharma OneSource 2025
From Octapharma OneSource HCP coding & coverage materials.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + Octapharma NDC (verify per bottle size) + ML + total volume in mL |
| HCPCS J1568 + JZ (or JW for waste) | 24D (drug line) | Units = total mg ÷ 500 (NOT total mg) |
| Drug units | 24G | Per the 500 mg unit basis — double-check the math |
| CPT 96365 (initial hour) | 24D (admin line) | One unit per infusion day |
| CPT 96366 (each additional hour) | 24D (admin line) | Bill quantity = number of additional hours past the first |
| ICD-10 | 21 | Indication-specific (D80–D83 for PI, D69.3 for ITP, M33.x for DM) |
| PA number | 23 | Required by all major payers for IVIG |
Phase 3
Get paid
PA is universal; payer-mandated brand and site-of-care are the recurring battlegrounds.
Payer policy snapshot Reviewed May 2026
All major payers require PA for IVIG. Brand preference, site-of-care steering, and indication-specific criteria vary.
| Payer | PA? | Brand preference / interchangeability | Site-of-care UM |
|---|---|---|---|
| UnitedHealthcare IVIG Medical Coverage Policy / MCG criteria |
Yes | Brand-agnostic for most indications; payer-mandated brand based on contract; DM requires FDA-labeled IVIG (Octagam 10% / Privigen 10%) | Aggressive — Optum-managed program steers HOPD to home/AIC |
| Aetna CPB 0206 (IVIG) + IVIG site-of-care policy |
Yes | Brand-agnostic; specific brand may be preferred per region | Yes (separate site-of-care policy; HOPD steered to AIC/home) |
| Cigna Coverage Policy 1206 |
Yes | Brand-agnostic; CarelonRx PBM may mandate specific brand | Yes; site-of-care UM via Carelon |
| BCBS plans Vary by plan |
Yes | Plan-specific; many BCBS plans align with FDA labeling and require labeled brand for DM | Plan-specific; most have IVIG site-of-care steering |
Step therapy
For dermatomyositis, most payers require failed first-line therapy (corticosteroids ± methotrexate, azathioprine, or MMF) before approving IVIG. Some allow IVIG as first-line for patients with contraindications to systemic immunosuppression (active infection, malignancy, severe diabetes). For PI, no step therapy — diagnosis confirmation drives approval. For ITP, IVIG is typically a recognized second-line option after corticosteroids; step therapy through other ITP agents (rituximab, TPO-RAs) is not generally required to access IVIG.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J1568
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6% per unit
$47.035
per 500 mg unit
Per mg basis
$0.094
$47.035 ÷ 500
Typical PI dose (28 g = 56 units)
$2,633.96
70 kg × 400 mg/kg
ITP day (70 g = 140 units)
$6,584.90
70 kg × 1 g/kg
DM cycle (140 g = 280 units)
$13,169.80
70 kg × 2 g/kg
PI annual (728 units)
$34,241.48
13 doses, 70 kg, 400 mg/kg
Lowest-cost major IVIG: J1568 currently sits below Privigen J1459, Gammagard
Liquid J1569, and Gamunex-C J1561 on Q2 2026 ASP+6%. The dollar-per-mg gap is small (~$0.005–
$0.006/mg) but at high-volume DM cycles (140–280 g per cycle, 13 cycles/year) the
annual difference per patient is meaningful for capitated and value-based contracts.
Coverage
No NCD specific to Octagam. Coverage falls under MAC LCDs for IVIG (e.g., NCD 250.3 for IVIG used for primary immunodeficiency in the home, MAC LCDs for other indications). All MACs cover J1568 for FDA-approved on-label indications with appropriate ICD-10 documentation.
Code history
- J1568 — permanent code, "Injection, immune globulin (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg"
- Both Octagam 5% and Octagam 10% bill under J1568 (not separate codes)
Patient assistance — Octapharma OneSource Octapharma verified May 2026
- Octapharma OneSource (Patient Assistance Program): 1-888-429-4535 — benefits investigation, prior authorization assistance, appeal support, financial assistance, free product for eligible uninsured/underinsured patients
- Commercial copay assistance: available through OneSource for eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
- Free drug program: for uninsured / underinsured patients meeting income requirements
- Foundations (Medicare patients): PAN Foundation, HealthWell Foundation, Patient Advocate Foundation — verify open IVIG funds quarterly
- Reimbursement support: Octapharma OneSource provides PA assistance, denial-management support, and claim resubmission help
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — J1568 pre-loaded.
Phase 4
Fix problems
Unit-basis errors, brand-mismatch denials, and HOPD site-of-care denials are the top three.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Units billed exceed reasonable | Billed mg as units instead of dividing by 500 | Divide total mg by 500. 28 g PI dose = 56 units, NOT 28,000 units. Correct the claim and resubmit. |
| Wrong admin code (96413/96415) | Chemo IV billed instead of therapeutic IV | Resubmit with 96365 + 96366. IVIG is non-chemo — chemo admin codes do not apply. |
| Brand mismatch (payer mandated different brand) | Octagam infused when payer formulary requires Privigen / Gammagard / Gamunex-C | Submit clinical justification (prior reaction to other brands, IgA-low requirement, etc.) or switch to mandated brand for next cycle. |
| Site of care (HOPD) | HOPD administration after first cycles on commercial plan with site-of-care UM | Move to AIC (POS 49) or home (POS 12 with home infusion vendor). Submit medical necessity letter if HOPD required. |
| JZ missing on adult claim | Single-dose container claim without JZ | Resubmit with JZ. Required since 7/1/2023 on every claim with no waste. |
| JW missing despite partial-bottle use | Wasted drug not reported when bottle exceeds dose | Add JW line for discarded units. JZ on the administered units; JW on the wasted units. |
| DM indication denied for Octagam 5% | 5% formulation does not have FDA DM approval | Switch to Octagam 10% (or other FDA-DM-approved IVIG) and resubmit. Document concentration in chart. |
| PI dose not justified | Dose outside 300–600 mg/kg range without IgG trough documentation | Submit IgG trough levels and titration history showing target trough rationale. |
| Step therapy not met (DM) | IVIG submitted without prior corticosteroid / DMARD trial | Submit prior therapy history, response, intolerance, or contraindication documentation. |
Frequently asked questions
What is the HCPCS code for Octagam?
Octagam is billed under HCPCS J1568 — "Injection, immune globulin (Octagam),
intravenous, non-lyophilized (e.g., liquid), 500 mg." Both Octagam 5% liquid and Octagam 10% liquid
bill under J1568 per CMS — there is no separate code for the 10% formulation. Critically,
1 unit = 500 mg (NOT 1 mg as with most J-codes). A 30 g (30,000 mg) dose bills as 60 units, not 30,000 units.
How many units do I bill for an Octagam dose?
Divide grams administered by 0.5 (or mg by 500). For example: a 70 kg patient receiving 400 mg/kg of Octagam 5% for primary immunodeficiency = 28,000 mg = 56 units. A 70 kg patient receiving 2 g/kg of Octagam 10% for dermatomyositis = 140,000 mg = 280 units (typically split across 2–5 days; bill per infusion day). Always confirm by dividing total mg by 500.
What administration CPT do I use for Octagam?
CPT 96365 (initial hour, therapeutic IV) plus 96366 for each additional hour.
Octagam is non-chemo, so chemo admin codes (96413/96415) do NOT apply. IVIG infusions for PI typically run
2–4 hours; dermatomyositis 2 g/kg cycles run multiple hours per day across 2–5 days. For each
infusion day, bill 96365 once + 96366 for each additional hour beyond the first.
What is the difference between Octagam 5% and Octagam 10%?
Both bill under J1568, but they have different FDA-approved indications:
Octagam 5% is approved for primary humoral immunodeficiency (PI) and chronic immune thrombocytopenic
purpura (ITP). Octagam 10% is approved for adult dermatomyositis (DM) — the
first IVIG with an FDA-approved DM indication (approved August 2021, ProDERM trial). The 10%
formulation is more concentrated (100 mg/mL vs 50 mg/mL), so it delivers the same gram dose in half the
volume — useful for high-volume regimens like 2 g/kg DM cycles.
Is Octagam approved for dermatomyositis?
Yes — Octagam 10% specifically. In August 2021, FDA approved Octagam 10% for adult dermatomyositis based on the ProDERM trial. It was the first IVIG to receive an FDA-approved DM indication. Standard regimen: 2 g/kg per cycle, divided over 2–5 consecutive days, repeated every 4 weeks. Use ICD-10 M33.0x (juvenile DM), M33.1x (other DM), M33.20–M33.29 (polymyositis with myopathy), or M33.9x (unspecified). Octagam 5% does NOT have the DM indication.
What is the Medicare reimbursement for J1568?
For Q2 2026, the Medicare Part B payment limit for J1568 is $47.035 per 500 mg unit (ASP + 6%) — equivalent to $0.094 per mg. This makes Octagam currently the lowest-cost IVIG among major brands. A 70 kg patient on 400 mg/kg Octagam 5% (28 g = 56 units) reimburses approximately $2,633.96 per infusion before sequestration. ASP is updated quarterly by CMS.
Is Octagam interchangeable with other IVIG brands?
Clinically, all major IVIG brands meet FDA potency and safety standards and are widely substituted. However, payer formulary contracts often mandate specific brands. Octagam's lowest-cost ASP positioning makes it attractive for value-based contracts, but verify per-payer; some payers prefer Privigen or Gammagard Liquid based on rebates. For dermatomyositis, payers typically permit only the FDA-labeled brand (Octagam 10% or Privigen 10%) without off-label justification. Brand switching mid-therapy is generally avoided due to differing osmolarities, sugar content, and IgA levels.
Does Octagam need premedication?
Premedication is common but not universally required. Acetaminophen and diphenhydramine 30–60 minutes before infusion are standard for many patients to prevent infusion-related reactions (headache, fever, chills). IV corticosteroids are added for patients with prior reactions or for high-dose dermatomyositis cycles. Adequate hydration is critical to reduce the risk of acute renal injury and thromboembolic events (boxed warning for all IVIG products).
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Octapharma USA — Octagam product information & OneSource HCP page
- DailyMed — OCTAGAM 5% and OCTAGAM 10% Prescribing Information
- FDA — Octagam 10% dermatomyositis approval announcement (August 2021)
- ProDERM trial — NEJM 2022 (Aggarwal R, et al.)
- CMS — Medicare Part B Drug ASP Pricing File
- UnitedHealthcare — Intravenous Immune Globulin (IVIG) Medical Coverage Policy
- Aetna CPB 0206 — Intravenous Immune Globulin
- American College of Rheumatology — Idiopathic inflammatory myopathy guidelines
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Brand interchangeability comparison | Quarterly | Refreshed alongside ASP file; tracks lowest-cost IVIG positioning. |
| Payer policies (UHC, Aetna, Cigna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, indication list | Event-driven | Tied to manufacturer document version + FDA label revision date. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
manufacturer, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify each cited
source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: Octapharma OneSource 2025. FDA label: Octagam 10% dermatomyositis approval August 2021. Both 5% and 10% liquid formulations bill under J1568. Lowest-cost major IVIG positioning verified Q2 2026.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list is verified against the current FDA label revisions for Octagam 5% and Octagam 10%.